Company Profile
Atara Biotherapeutics, Inc. Stock Price, News & Analysis
- Ticker:
- ATRA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
8.25 USD (-3.40%)
Close
Last updated: August 6, 2026
89.2M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, ATRA closed down 3.40% at $8.25. No new same-company headline was identified in the current news window.
Company overview
Allogeneic EBV T-Cell Platform
Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.
Tabelecleucel
Tabelecleucel is intended for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease and is supported by the pivotal single-arm ALLELE study.
Partnered Regulatory Model
Pierre Fabre Pharmaceuticals controls the U.S. regulatory and commercial program, while Atara retains economic exposure and platform expertise.
Future catalysts
Pierre Fabre plans to include additional patients and longer follow-up in a tabelecleucel BLA resubmission package.
Atara expects to provide a further regulatory update in the third quarter of 2026.
Recent news
- 01
Atara Biotherapeutics Announces Changes to Its Board of Directors
Source: Atara Biotherapeutics, Inc.
- 02
Atara Biotherapeutics Announces First Quarter 2026 Financial Results and Operational Progress
Source: Atara Biotherapeutics, Inc.
- 03
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel
Source: Atara Biotherapeutics, Inc.
- 04
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress
Source: Atara Biotherapeutics, Inc.
- 05
Atara Biotherapeutics Provides a Business Update
Source: Atara Biotherapeutics, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Atara Biotherapeutics, Inc. (ATRA)?
Atara Biotherapeutics, Inc. (ATRA) most recently closed at 8.25 USD, a -3.40% move versus the previous session.
What is the market cap of Atara Biotherapeutics, Inc. (ATRA)?
Atara Biotherapeutics, Inc. currently has a market capitalization of 89.2M USD on BioPharmSignal.
What does Atara Biotherapeutics, Inc. do?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Tabelecleucel Tabelecleucel is intended for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease and is supported by the pivotal single-arm ALLELE...
On which exchange is ATRA stock listed?
Atara Biotherapeutics, Inc. (ATRA) is associated with NASDAQ, United States, Biopharma.
What is Allogeneic?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.
Which conditions is Atara Biotherapeutics, Inc. targeting with Allogeneic?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens. Tabelecleucel Tabelecleucel is intended for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease and is supported by the pivotal single-arm ALLELE...
How does Atara Biotherapeutics, Inc. describe recent progress with Allogeneic?
Pierre Fabre plans to include additional patients and longer follow-up in a tabelecleucel BLA resubmission package. Atara expects to provide a further regulatory update in the third quarter of 2026.
What is T-Cell?
Allogeneic EBV T-Cell Platform Atara Biotherapeutics develops off-the-shelf T-cell therapies generated from healthy donors and directed against Epstein-Barr virus antigens.